Alcoholic and Non-alcoholic Fatty Liver Disease

Alcoholic and Non-alcoholic Fatty Liver Disease

Alcoholic and Non-alcoholic Fatty Liver Disease

On this page

Overview & Definitions - Liver's Fatty Foes

  • Hepatic Steatosis: Abnormal lipid accumulation in >5% hepatocytes.
  • AFLD (Alcoholic FLD): Steatosis from chronic significant alcohol (e.g., >20-30g/d M, >10-20g/d F).
  • NAFLD (Non-alcoholic FLD): Steatosis with no/minimal alcohol; component of metabolic syndrome.
  • Steatohepatitis (ASH/NASH): Steatosis with inflammation & hepatocyte injury (e.g., ballooning). Histological spectrum of NAFLD and NASH

⭐ NAFLD is the most common chronic liver disease, with rising prevalence globally.

Pathogenesis Pathways - How Fat Happens

  • ↑ FA Delivery/Uptake to Liver:
    • NAFLD: Insulin resistance (IR) in adipose tissue → ↑ peripheral lipolysis → ↑ FFAs to liver.
  • ↑ De Novo Lipogenesis (DNL) in Liver:
    • AFLD: Ethanol metabolism → ↑NADH/NAD+ ratio, shunting substrates to FA synthesis.
    • NAFLD: IR & hyperinsulinemia activate SREBP-1c (key lipogenic TF).
  • ↓ FA β-oxidation in Mitochondria:
    • AFLD: ↑NADH/NAD+ ratio inhibits mitochondrial β-oxidation.
    • NAFLD: Mitochondrial dysfunction & oxidative stress impair FA breakdown.
  • ↓ VLDL Export from Liver:
    • AFLD: Acetaldehyde impairs microtubule function & apoprotein synthesis for VLDL.
    • NAFLD: Impaired ApoB-100 synthesis or VLDL assembly/secretion.

⭐ PNPLA3 variants link to NAFLD & alcoholic cirrhosis, impairing triglyceride hydrolysis.

Microscopic Mayhem - Biopsy Breakdown

  • Steatosis: Macrovesicular (large lipid droplets displacing nucleus).
    • NAFLD: Often Zone 3 (perivenular) predominant.
  • Hepatocyte Injury:
    • Ballooning degeneration (swollen hepatocytes, rarefied cytoplasm).
    • Apoptotic bodies (acidophilic).
  • Mallory-Denk Bodies (MDBs):
    • Eosinophilic, irregular, ropey intracytoplasmic inclusions (cytokeratins 8/18).
    • Highly characteristic of AFLD; also seen in NASH.
  • Inflammation:
    • AFLD: Predominantly neutrophils, often surrounding damaged hepatocytes (satellitosis).
    • NASH: Mixed lobular infiltrate (lymphocytes, macrophages, fewer neutrophils).
  • Fibrosis:
    • Perisinusoidal/pericellular ("chicken-wire") pattern, typically begins in Zone 3.
    • Can progress to bridging fibrosis and ultimately cirrhosis.

Liver biopsy: steatosis, ballooning, inflammation

⭐ Mallory-Denk bodies, composed of tangled cytokeratin filaments (CK8/18) and ubiquitin, are a key indicator of severe hepatocyte injury.

Clinical Clues & Diagnosis - Spotting the Steatosis

  • Symptoms: Often silent. NAFLD linked to metabolic syndrome; AFLD to alcohol use. Fatigue, RUQ discomfort possible.
  • Key Labs:
    • AFLD: AST/ALT ratio > 2 (📌 Alcohol Superior to Alanine), ↑GGT.
    • NAFLD: ALT > AST (ratio < 1).
    • Assess for fibrosis: FIB-4 score $ (Age \times AST) / (Platelets \times \sqrt{ALT}) $.
  • Imaging:
    • Ultrasound (USG): Initial, shows hyperechoic "bright liver".
    • Transient Elastography (FibroScan): Measures steatosis (CAP) & fibrosis.
  • Liver Biopsy: Gold standard for diagnosis/staging (e.g., NASH if NAS ≥ 5). AFLD: Mallory-Denk bodies.

Ultrasound: Normal vs. Grade 1 Fatty Liver

⭐ In AFLD, the AST:ALT ratio is typically > 2, whereas in NAFLD, it's usually < 1. This difference is a key diagnostic clue.

Progression & Perils - Fatty Liver's Fate

  • Silent Progression: Often asymptomatic until advanced stages.
  • Fibrosis is Key: Determines prognosis; bridging fibrosis (F3) to cirrhosis (F4) critical.
  • Cirrhotic Complications: Portal hypertension, liver failure, coagulopathy.
  • HCC Risk: Significantly ↑ with cirrhosis; also present in non-cirrhotic NASH.

⭐ About 20-30% of NASH patients progress to cirrhosis; HCC risk ↑ 5-10 fold with cirrhosis.

Fatty Liver Disease Progression

High‑Yield Points - ⚡ Biggest Takeaways

  • NAFLD is strongly associated with metabolic syndrome and insulin resistance; AFLD with chronic alcohol abuse.
  • Both show steatosis (fatty liver), which can progress to steatohepatitis, fibrosis, and cirrhosis.
  • Mallory-Denk bodies (intracytoplasmic hyaline) are characteristic, especially in AFLD.
  • An AST/ALT ratio >2 is suggestive of AFLD; ALT > AST is more common in NAFLD.
  • Weight loss and lifestyle modification are crucial for NAFLD management; alcohol abstinence is essential for AFLD.
  • Both conditions significantly increase the risk of hepatocellular carcinoma (HCC), particularly with established cirrhosis.
Rezzy AI Tutor

Have doubts about this lesson?

Ask Rezzy, our AI tutor, to explain anything you didn't understand

Practice Questions: Alcoholic and Non-alcoholic Fatty Liver Disease

Test your understanding with these related questions

A 50-year-old man with a history of alcohol abuse is found to have elevated liver enzymes, and a liver biopsy shows the microscopic features of steatosis. If the patient abstains from further drinking, this condition will most likely evolve into which of the following?

1 of 5

Flashcards: Alcoholic and Non-alcoholic Fatty Liver Disease

1/10

_____ pattern is seen on trichrome staining of liver biopsy specimen in alcoholic hepatitis

TAP TO REVEAL ANSWER

_____ pattern is seen on trichrome staining of liver biopsy specimen in alcoholic hepatitis

Chicken-wire fence

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start For Free
Alcoholic and Non-alcoholic Fatt... - Free Indian Medical PG